美国HIV诊断时基因型检测的临床影响与成本效益
研究使用成本效益模型评估美国HIV诊断时基线基因型检测在采用DTG联合NRTI方案启动ART时的临床影响与成本效益。结果显示,与不检测相比,基线基因型仅增加<1个质量调整生命日,每人多花费500美元,增量成本效益比为42万美元/质量调整生命年,不具有成本效益。结论认为在当前INSTI一线方案下,基线基因型检测临床获益极小且不具成本效益。
要点
- 基线基因型检测仅增加<1个质量调整生命日,每人多花费500美元。
- 增量成本效益比为42万美元/质量调整生命年,不具成本效益。
- 仅当DTG方案对传播性NRTI耐药抑制率≤50%等不太可能条件下才具成本效益。
核心结论
- 在美国以INSTI为基础的一线方案下,基线基因型检测临床获益极小且不具成本效益。
研究设计与样本
- 使用成本效益模型(Cost-effectiveness of Preventing AIDS Complications模型)比较基线基因型检测与不检测,对象为启动DTG联合NRTI方案ART的HIV感染者。
主要发现
- 基线基因型检测仅增加<1个未贴现质量调整生命日,每人多花费500美元,增量成本效益比为42万美元/质量调整生命年。
- 单因素敏感性分析中,对所有新诊断HIV感染者,基线基因型的临床获益从未超过5个质量调整生命日。
- 仅当当前TDR患病率下出现不太可能条件时(如DTG方案对传播性NRTI耐药抑制率≤50%),基线基因型才具成本效益。
关键数值与推荐
- 无传播性耐药者占83.8%,基线基因型不改变方案选择。
- 传播性NRTI耐药者占5.8%,基线基因型指导NRTI选择并影响不良事件后后续ART(DTG不良事件率14%)。
- 传播性NNRTI耐药者占7.2%,基线基因型仅影响因DTG不良事件换用NNRTI方案者的医疗。
- 48周病毒学抑制率随TDR不同在40%-92%之间变化。
- 成本包括基因型检测320美元/次和ART 2500-3000美元/月。
临床怎么用
- 在美国INSTI一线方案背景下,不应常规进行基线基因型检测。
局限性
- 模型研究,结论依赖输入参数与假设;成本效益结果基于美国医疗成本环境。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: US guidelines recommend genotype testing at human immunodeficiency virus (HIV) diagnosis ("baseline genotype") to detect transmitted drug resistance (TDR) to nonnucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease inhibitors. With integrase strand inhibitor (INSTI)-based regimens now recommended as first-line antiretroviral therapy (ART), the of baseline genotypes is uncertain. METHODS: We used the Cost-effectiveness of Preventing AIDS Complications model to examine the clinical impact and cost-effectiveness of baseline genotype compared to no baseline genotype for people starting ART with dolutegravir (DTG) and an NRTI pair. For people with no TDR (83.8%), baseline genotype does not alter regimen selection. Among people with transmitted NRTI resistance (5.8%), baseline genotype guides NRTI selection and informs subsequent ART after adverse events (DTG AEs, 14%). Among people with transmitted NNRTI resistance (7.2%), baseline genotype influences care only for people with DTG AEs switching to NNRTI-based regimens. The 48-week virologic suppression varied (40%-92%) depending on TDR. Costs included $320/genotype and $2500-$3000/month for ART. RESULTS: Compared to no baseline genotype, baseline genotype resulted in <1 additional undiscounted quality-adjusted life-day (QALD), cost an additional $500/person, and was not cost-effective (incremental cost-effectiveness ratio: $420 000/quality-adjusted life-year). In univariate sensitivity analysis, clinical benefits of baseline genotype never exceeded 5 QALDs for all newly diagnosed people with HIV. Baseline genotype was cost-effective at current TDR prevalence only under unlikely conditions, eg, DTG-based regimens achieving ≤50% suppression of transmitted NRTI resistance. CONCLUSIONS: With INSTI-based first-line regimens in the United States, baseline genotype offers minimal clinical benefit and is not cost-effective.
引用
- Hyle EP, Scott JA, Sax PE, et al. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States. Clin Infect Dis. 2020. PMID: 31055599. doi:10.1093/cid/ciz372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。